Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination With rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy

Next Previous
Trial Profile

A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination With rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 01 May 2023 The boosting schedule was amended mid-trial to weeks 3, 5 and9 to allow for earlier surgeries, as per results presented at the 118th Annual Meeting of the American Urological Association.
  • 01 May 2023 Results (Between 2014-2016, n=26) assessing the surgical safety and feasibility outcomes of patients investigating the neoadjuvant use of this vaccinetherapy in patients with localized PCa, presented at the 118th Annual Meeting of the American Urological Association.
  • 05 Jun 2018 Results assessing the effect of galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate, presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top